Your browser of choice has not been tested for use with If you have issues, please download one of the browsers listed here.

Express Scripts (ESRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.


See More
  • Market Capitalization, $K 52,061,192
  • Shares Outstanding, K 563,860
  • Annual Sales, $ 100,065 M
  • Annual Income, $ 4,517 M
  • 60-Month Beta 0.88
  • Price/Sales 0.54
  • Price/Cash Flow N/A
  • Price/Book 2.53
  • Price/Earnings ttm 11.17
  • Earnings Per Share ttm 8.58
  • Most Recent Earnings 2.43 on 10/31/18
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 2.67
  • Number of Estimates 10
  • High Estimate 2.77
  • Low Estimate 2.58
  • Prior Year 2.16
  • Growth Rate Est. (year over year) +23.61%

Price Performance

See More
Period Period Low Period High Performance
92.11 +0.24%
on 12/20/18
101.73 -9.24%
on 12/03/18
-2.96 (-3.11%)
since 11/20/18
91.92 +0.45%
on 10/24/18
101.73 -9.24%
on 12/03/18
-2.71 (-2.85%)
since 09/20/18
66.93 +37.95%
on 04/02/18
101.73 -9.24%
on 12/03/18
+18.34 (+24.79%)
since 12/20/17

Most Recent Stories

More News
Express Scripts Simplifies Digital Health Technology Marketplace for Consumers and Payers

To make it simpler for consumers and payers to navigate the hundreds of thousands of currently available personal health technologies and interventions, Express Scripts, a Cigna company, will introduce...

ESRX : 92.33 (-3.62%)
Medvantx Expanding Pharmacy Team to Include Chief Pharmacy Officer - Focusing on Innovation and Quality Systems to Support Company's Novel E-Commerce Enabled Direct to Patient Pharmacy Channel

Medvantx, Inc., the leading provider of ecommerce enabled pharmacy solutions, is pleased to announce the addition of Slater Nash, as Chief Pharmacy Officer. Slater joins Medvantx from Express Scripts,...

ESRX : 92.33 (-3.62%)
Titan Pharmaceuticals Further Expands Patient Access To Probuphine® Via Product Purchase And Supply Agreement With Express Scripts' Specialty Pharmacy, Accredo®

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that it has executed a product purchase and supply agreement with Accredo specialty pharmacy, a subsidiary of Express Scripts, further expanding...

ESRX : 92.33 (-3.62%)
TTNP : 1.41 (-0.70%)
Express Scripts Ranked as a Top 50 Inclusive Company by DiversityInc

Express Scripts, through its commitment to diversity and inclusion, has earned recognition among the Top 50 inclusive companies in the nation by DiversityInc. This recognition includes being named the...

ESRX : 92.33 (-3.62%)
Express Scripts Canada 2019 Prescription Drug Trend Report - nonadherence an alarming trend

Depending on the conditions for which they are being treated, as many as 70 percent of Canadian patients are not taking their medications as directed by their physicians. These statistics are among the...

ESRX : 92.33 (-3.62%)
Express Scripts and Appriss Health Create New Military Health System Prescription Drug Monitoring Program

Express Scripts, one of the nation's leading pharmacy benefit managers, and Appriss Health, provider of the most comprehensive prescription drug monitoring platform for addressing substance use disorder...

ESRX : 92.33 (-3.62%)
Accredo, a Full-Service Specialty Pharmacy, Expands Best-in-Class Services with New Pharmacy in Hawaii

Express Scripts today announced that its specialty pharmacy, Accredo, will open a new location in Honolulu to provide high-touch pharmacy care to people living with chronic, complex health conditions,...

ESRX : 92.33 (-3.62%)
Express Scripts Down 3.4% Since SmarTrend Downtrend Call (ESRX)

SmarTrend identified a Downtrend for Express Scripts (NASDAQ:ESRX) on December 10th, 2018 at $95.57. In approximately 4 months, Express Scripts has returned 3.39% as of today's recent price of $92.33....

ESRX : 92.33 (-3.62%)
MAVENCLAD® (Cladribine) Tablets Now Covered by Express Scripts

EMD Serono, Inc. today announced that Express Scripts is covering on its formulary the oral multiple sclerosis (MS) therapy, MAVENCLAD® (cladribine) tablets, which was approved by the U.S. Food and Drug...

ESRX : 92.33 (-3.62%)
Cigna and Express Scripts Further Enhance Customer Service Offerings Through New Collaboration with Amazon Alexa

Cigna and Express Scripts have collaborated with Amazon Alexa to launch two voice skills to make health care more engaging, personalized and convenient for customers. The Cigna and Express...

ESRX : 92.33 (-3.62%)
CI : 150.01 (-1.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade ESRX with:

Business Summary

Express Scripts Holding Company puts medicine within reach of tens of millions of people by aligning with plan sponsors, taking bold action and delivering patient-centered care to make better health more affordable and accessible. Headquartered in St. Louis, Express Scripts provides integrated pharmacy...

See More

Key Turning Points

2nd Resistance Point 97.20
1st Resistance Point 94.76
Last Price 92.33
1st Support Level 91.00
2nd Support Level 89.68

See More

52-Week High 101.73
Last Price 92.33
Fibonacci 61.8% 88.44
Fibonacci 50% 84.33
Fibonacci 38.2% 80.22
52-Week Low 66.93

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar